stoxline Quote Chart Rank Option Currency Glossary
Orchard Therapeutics plc (ORTX)
16.7  0.05 (0.3%)    01-23 16:00
Open: 16.65
High: 16.72
Volume: 372,349
Pre. Close: 16.65
Low: 16.635
Market Cap: 380(M)
Technical analysis
2024-03-08 4:53:58 PM
Short term     
Mid term     
Targets 6-month :  19.52 1-year :  22.8
Resists First :  16.71 Second :  19.52
Pivot price 16.63
Supports First :  16.5 Second :  16.37
MAs MA(5) :  16.7 MA(20) :  16.57
MA(100) :  14.65 MA(250) :  8.92
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  93.9 D(3) :  93.9
RSI RSI(14): 85.3
52-week High :  16.71 Low :  4.23
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ORTX ] has closed below upper band by 32.9%. Bollinger Bands are 85.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 68 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.74 - 16.82 16.82 - 16.89
Low: 16.47 - 16.58 16.58 - 16.67
Close: 16.54 - 16.71 16.71 - 16.85
Company Description

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Headline News

Fri, 21 Jun 2024
Analyst Forecasts For Orchard Therapeutics plc (NASDAQ:ORTX) Are Surging Higher - Yahoo Movies UK

Thu, 20 Jun 2024
Orchard Therapeutics PLC Sponsored ADR (ORTX) Now Trades Above Golden Cross: Time to Buy? - Yahoo Sport Australia

Thu, 25 Jan 2024
Orchard Therapeutics' Shareholder Rights Altered Post-Acquisition - - TipRanks

Thu, 25 Jan 2024
Orchard Therapeutics ADSs Delisting from Nasdaq - - TipRanks

Wed, 24 Jan 2024
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases - GlobeNewswire

Fri, 19 Jan 2024
Orchard Therapeutics (ORTX): Still An Attractive Merger Arbitrage Opportunity - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 23 (M)
Shares Float 118 (M)
Held by Insiders 12.2 (%)
Held by Institutions 103.5 (%)
Shares Short 31 (K)
Shares Short P.Month 41 (K)
Stock Financials
EPS -4.1
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.52
Profit Margin 0 %
Operating Margin -342.9 %
Return on Assets (ttm) -29.3 %
Return on Equity (ttm) -71.5 %
Qtrly Rev. Growth 9.1 %
Gross Profit (p.s.) 0
Sales Per Share 0.95
EBITDA (p.s.) -4.37
Qtrly Earnings Growth 0 %
Operating Cash Flow -93 (M)
Levered Free Cash Flow -50 (M)
Stock Valuations
PE Ratio -4.08
PEG Ratio 0
Price to Book value 4.73
Price to Sales 17.4
Price to Cash Flow -4.08
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android